In 2014, we have seen the highest number of initial public offerings since 2000. Over 90 healthcare/life sciences IPOs have priced so far this year with an average total return of 14.5%. Will the next set of biotech companies with healthy trajectories be ready for a 2015 IPO? Join Fenwick & West and Piper Jaffray & Co. for a complimentary program to help identify the key steps in planning for public company readiness.
This 60-minute interactive meeting will highlight:
- Key lessons learned from recent offerings
- What’s new in capital markets
- Update on recent regulatory developments
- Key pre- and post-IPO infrastructure considerations